Study Of TNG260 And An Anti-PD Antibody In STK11 Mutated Solid Tumors
Portfolio Pulse from Happy Mohamed
A clinical trial is being conducted to study the effects of TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation. The trial aims to determine the recommended dose for Phase 2, evaluate safety and tolerability, and assess the initial antineoplastic activity.
June 02, 2023 | 2:50 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
The clinical trial of TNG260 in combination with pembrolizumab for STK11 mutated solid tumors may impact TNGX's stock price depending on the trial's results.
The clinical trial is directly related to TNGX's product, TNG260. Positive results from the trial may lead to increased investor confidence and a potential rise in stock price, while negative results may have the opposite effect. However, as the trial is still in progress, the short-term impact on the stock price remains uncertain.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100